News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

STADA Arzneimittel (STAGn.DE) Names A New CEO, It's Fourth In The Last 15 Months



9/1/2017 6:28:40 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Bain Capital and Cinven announce intention to nominate new CEO and CFO for STADA once new composition of Supervisory Board is effective

  • Decision follows statements by current CEO and CFO in the STADA AGM 2017 announcing their readiness to step down from their interim positions in due course
  • Claudio Albrecht shall be appointed as CEO and Mark Keatley as CFO subject to approval by the Supervisory Board of STADA
  • New leadership team with strong track record in driving growth strategies for major companies in the generics sector

Frankfurt / Munich, 1 September 2017 - Bain Capital and Cinven announce their intention to nominate Claudio Albrecht as new Chief Executive Officer and Mark Keatley as new Chief Financial Officer of STADA Arzneimittel AG. Prior to this, the current CEO Engelbert Coster Tjeenk Willink and CFO Dr Bernhard D?ttmann had announced at the STADA Annual General Meeting that they would be ready to step down from their interim positions before expiry of their contracts following the successful completion of the public takeover by Bain Capital and Cinven. In line with German Corporate Governance, the actual appointment of Claudio Albrecht and Mark Keatley will be decided upon by the Supervisory Board of STADA once its new members have been appointed by Court.

Bain Capital and Cinven thank Mr Tjeenk Willink and Dr D?ttmann for their significant contribution and excellent leadership over the past months. In the interest of all stakeholders of STADA, both shareholders will work with the newly composed Supervisory Board of the Company towards a fast transition from the current to the new Executive Board while ensuring continuity. Dr Barthold Piening, Chief Technical Officer of STADA, will remain in his position.

Claudio Albrecht and Mark Keatley both have unique backgrounds in the global generics industry, where they have led highly successful growth strategies at major corporations. Claudio Albrecht was Chief Executive Officer and Chairman of generics company Actavis Group until its sale to Watson in 2012. Under his leadership, Actavis grew its revenues to over EUR 2 billion and expanded its international footprint significantly. Previously, he had been CEO of Ratiopharm Group, having started his career in the generics business of Sandoz.

Mark Keatley served as Chief Financial Officer of Actavis Group until its sale in 2012. He also has strong expertise in managing growth and transformation strategies in the generics industry and beyond. Previously he was CFO of Famar, a European contract manufacturer for the healthcare industry. He has also worked in medical diagnostic services, investment banking and private equity.

Claudio Albrecht and Mark Keatley have most recently worked at Albrecht, Prock & Partners, a global strategy consulting firm with a focus on the pharmaceutical and healthcare industry. Over the past years they have advised on multiple major engagements in the generics and broader healthcare sector, including supporting Bain Capital and Cinven during the due diligence process ahead of the successful takeover offer.

Michael Siefke, Managing Director at Bain Capital and Bruno Schick, Partner at Cinven said: "We are very pleased that Claudio Albrecht and Mark Keatley have decided to join STADA as the new CEO and CFO. With their significant expertise in managing comprehensive global growth and transformation strategies in the generics industry, they are uniquely qualified to lead STADA into the next phase of expansion. It was previously intended that Claudio Albrecht would join the Supervisory Board of STADA alongside the representatives of the new majority shareholders. Cinven and Bain Capital have now asked him to step in as CEO, subject to approval of the Supervisory Board, to lead the process of transition to a privately held company, and we are delighted that he has accepted this role. In due course, we expect him to join the STADA group in a Non-Executive role as originally envisaged once a CEO has been recruited who will lead STADA in the long run. We would also like to thank Engelbert Coster Tjeenk Willink and Dr Bernhard D?ttmann for their excellent service to the company, and their readiness to lead a challenging process towards what is now a stable ownership structure and promising future."


Media contacts:

For Bain Capital
Hazel Stevenson                                           
T   +44 (0) 20 375 74 989                                   
M  +44 (0) 798 600 97 20                            
E   [email protected]         
 
Ed Gascoigne-Pees
T   +44 (0) 20 375 74 984
M +44 (0) 788 400 19 49
E   [email protected]
 
 
For Cinven
Vanessa Maydon                                          
T   +44 (0) 20 766 13325                              
M +44 (0) 7802 961 902                              
E   [email protected]
 
Lutz Golsch
T   +49 69 92037 110                                   
M +49 173 651 7710
E   [email protected]


About Bain Capital Private Equity:

Bain Capital Private Equity has partnered closely with management teams to provide the strategic resources that build great companies and help them thrive since its founding in 1984. Bain Capital's global team of approximately 220 investment professionals creates value for its portfolio companies through its global platform and depth of expertise in key vertical industries including healthcare, consumer/retail, financial and business services, industrials, and technology, media and telecommunications. Bain Capital has offices in Boston, Chicago, New York, Palo Alto, San Francisco, Dublin, London, Luxembourg, Munich, Melbourne, Mumbai, Hong Kong, Shanghai, Sydney and Tokyo and has made investments in more than 300 companies to date. In addition to private equity, Bain Capital invests across asset classes including credit, public equity and venture capital, managing approximately USD 75 billion in total and leveraging the firm's shared platform to capture opportunities in strategic areas of focus.

For more information, visit www.baincapitalprivateequity.com


About Cinven:

Cinven is a leading international private equity firm focused on building world-class European and global companies. Its funds invest in six key sectors: Healthcare, Business Services, Consumer, Financial Services, Industrials, and Technology, Media and Telecommunications (TMT). Cinven has offices in key locations including: Frankfurt, London, Paris, Milan, Madrid, Hong Kong, and New York. Since 1988, Cinven funds have invested in 120 companies worth around EUR90 billion. Today Cinven has more than EUR15 billion in assets under management. Cinven takes a responsible approach towards its portfolio companies, their employees, suppliers, local communities, the environment and society.

For more information, please visit www.cinven.com



01.09.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES